Abstract. There is little information regarding the recent trend of synchronous and metachronous pulmonary metastases in patients with primary colorectal cancer. We investigated patients with sporadic colorectal cancer who underwent surgery in our department between 1990 and 2009. Clinicopathological parameters of primary cancer and lung metastases and survival time were retrospectively reviewed. Of the 2,286 patients included in this study, 64 (2.8%) had synchronous lung metastases at the time of colorectal surgery. A total of 18 patients (28%) received pulmonary metastasectomy for these lesions with curative intent. Out of 2,082 curatively operated cases, 212 (10.2%) developed metachronous lung metastases. The frequency of synchronous and/ or metachronous lung metastases detected in curative cases increased from 8.9% in the 1990s to 11.9% in the 2000s (p=0.03). Among predictive factors for metachronous lung metastases, the presence of distant organ metastases, i.e. initial stage IV, significantly increased over time. Notably, patients with unresectable metachronous lung metastases in the 2000s, characterized by smaller size, exhibited more favorable prognosis than in the 1990s (p=0.003). Recent improvement of imaging modalities is considered to have facilitated the prompt diagnosis of lung metastases. Moreover, marked progress in multidisciplinary treatment has presumably achieved more favorable prognosis in an increasing number of patients with advanced colorectal cancer.
Introduction
Recent epidemiological studies have revealed that colorectal cancer (CRC) ranks among the leading malignancies in incidence in Western countries and Japan (1) (2) (3) . It is well known that the lung is the most common extra-abdominal site of metastasis from primary CRC (4) . Approximately 10-20% of surgical CRC cases develop lung metastases (5) . In consideration of the vast prevalence of CRC and of the marked progress in diagnostic and treatment options, we anticipate more opportunities to detect lung metastases; however, there is still a paucity of detailed data on these issues in the literature.
In this study, we retrospectively investigated the features of metastasized lung tumors observed in over 2,000 surgical cases of sporadic CRC in a representative university hospital in Japan. Moreover, we assessed the risk factors for lung metastases in CRC patients and analyzed recent trends in frequency and survival.
Patients and methods

Patients.
Patients with primary CRC who underwent surgery in our hospital between January 1990 and December 2009 were enrolled in this study. The subjects included those with i) inflammatory bowel disease-associated cancer, ii) synchronous multiple cancers of the colorectum, iii) cancer with simultaneous malignancies in other organs and iv) patients who had undergone palliative surgery for primary CRC. The exclusion criteria were i) cancer arising in patients diagnosed with familial adenomatous polyposis or Lynch syndrome, ii) anal fistula-associated cancer, iii) locally recurrent tumor alone in previously resected CRC, and iv) metastasized tumors in the colorectum originating from other primary organs. For analyses of metachronous lung tumors, only patients who had undergone curative surgery (R0) for primary CRC were assembled. Written, informed consent was obtained from each patient participating in this study.
Synchronous tumors. Synchronous tumors were defined as those cases in which lesions were observed prior to or within 3 months after the surgery for CRC, and were otherwise judged as metachronous tumors. There is no definite consensus regarding synchronous and metachronous metastases; however, we set this cut-off time-point, since the first opportunity for follow-up image study occurred at 3 postoperative months, as mentioned below, in our institution. Patients with lower rectal cancer were often treated with preoperative chemoradiation therapy, once there was no clear distant metastasis. Certain CRC patients with massive liver metastases received systemic chemotherapy prior to surgery. Pulmonary tumors revealed during such neoadjuvant therapies, for example, were defined as synchronous tumors. shorter duration of follow-up, was significantly higher than in 1990-1999 (8.5%, p=0.04). In these patients, the resection rate was 51% for the first decade and 38% for the second. The total frequency of lung metastases in CRC patients in their lifetime was significantly higher in the second decade (11.9%) than in the first (8.9%, p=0.03).
Synchronous and metachronous lung metastases in
Factors affecting the appearance of lung metastases in CRC patients undergoing curative surgery. To identify risk factors related to the appearance of lung metastases, clinicopathological parameters of CRC cases with metachronous lung metastases were compared with the other cases. Univariate analysis revealed that age, location, size and depth of primary CRC, regional lymph node metastasis, distant organ metastasis and a family history of CRC were correlated with lung metastases (Table III) . These parameters were further subjected to multivariate logistic regression analysis. The results revealed that a tumor in the rectum [odds ratio (OR)=2.450] and the presence of lymph node metastasis (OR=2.967) and distant organ metastases (OR=4.185) were independent predictive factors for metachronous lung tumors in CRC (p<0.0001, Table IV ). 1990-1999 and 2000-2009 . To investigate the causes for the increased lung metastases in CRC patients, the profiles of curative CRC cases were compared between 1990-1999 and 2000-2009. As shown in Table V , gender and ECOG PS distributions were similar between the groups. Surgery was performed on older patients in 2000-2009 than in 1990-1999 (average ages: 65.5 and 62.2 years, respectively; p<0.0001). The size of primary CRC was smaller in the second period (mean diameter: 40.9 mm) than in the first (43.9 mm, p=0.005). Throughout the 2 decades, >90% of histology was differentiated adenocarcinoma. The rectum was the most common location (42%) in both decades, although there was a difference in the locations of primary colon cancers between the 2 time periods. There were no significant changes in the distribution of pathological T and N numbers; however, more stage IV CRC patients (M1) underwent curative surgery in 2000-2009 than in 1990-1999 (9% vs. 6%). In 1990-1999, 5% of the patients had first-degree relative(s) with CRC, whereas 9% had a positive family history of CRC in 2000-2009 (p=0.01). There was no intergroup difference in the percentage of current or ex-smokers (54% and 56% for 1990-1999 and 2000-2009, respectively, p=0.76).
Comparison of clinicopathological parameters of CRC patients between
Survival of CRC patients according to the onset of lung metastases and time period.
In synchronous lung metastases, the 5-year survival rate of patients who underwent pulmonary (6) metastasectomy (n=18) was 65%. There was no surgery-related mortality. On the contrary, patients who had not undergone pulmonary metastasectomy (n=46) succumbed to the disease in less than 4.2 years (p=0.0003, data not shown).
With regard to metachronous lung metastases, the 5-year survival rate following diagnosis of lung metastases was 60% for cases of metastasectomy (n=89), whereas it was only 15% for other palliative cases (n=123) (p<0.0001, data not shown). In order to reveal any chronological changes in survival of these patients, they were further subdivided according to the calendar period. The survival curves of patients who received lung resection for metastasized tumors were similar between the 2 time periods. Their 5-year survival rate was 58% for the first decade, and 63% for the second (p=0.85, Fig. 1A) . Notably, patients without metastasectomy survived significantly longer in 2000-2009 than in 1990-1999 (p=0.003). Only 19% survived 2 years in the 1990-1999 group, whereas 48% survived for the same duration in 2000-2009, due to non-surgical treatment for lung metastases (Fig. 1B) . A, All cases. Table VI , the frequencies of multiple, bilateral metastases, elevated carcinoembryonic antigen (CEA) levels in the serum and the presence of other organ metastases at the time of diagnosis did not vary significantly between the time periods. Disease-free interval (DFI) tended to be shorter in the 2000s, but the difference did not reach statistical significance. Only the diameter of the largest lung deposit was significantly smaller in patients in the 2000s (mean, 9.8±7.9 mm) than in the 1990s (mean, 17.7±15.0 mm; p=0.01).
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Discussion
Recent progress in multimodal treatments for CRC has achieved a more favorable prognosis. An increasing number of advanced CRC patients, even those with distant metastases, have the opportunity to undergo curative surgery following state-of-the-art neoadjuvant chemotherapy and radiation therapy, and consequently are likely to survive for longer than they previously would have (7) . Given these trends, we envisioned that doctors would encounter lung metastases more frequently in the postoperative follow-up. Data collected over a period of 20 years from our institution have clearly demonstrated that the overall incidence of lung metastases in curative CRC cases has risen from 8.9% in 1990-1999 to 11.9% in 2000-2009 (Table II) . Due to a shorter follow-up duration, the true frequency in the second decade may actually be higher.
Our observation that lung metastases have increased over time in CRC patients was partially consitent with a study by Mitry et al based on their experience between 1976 and 2005 (8) . They revealed that the risk of synchronous metastases in the lung was 3.77 times higher in 1996-2005 than in 1976-1985. However, we also found a significant increase in metachronous lung tumors in 2000-2009 as compared to 1990-1999, which differed from their results. The increasing incidence of synchronous metastases may be attributable to the improvement of diagnostic tools, such as CT scans (9); however, the high detection rate of metachronous lung tumors is not explained simply by the improved quality of imaging modalities, since these malignant lesions will grow and be detected eventually. In order to investigate which other factors caused lung deposits to be detected more often in 2000-2009 than in 1990-1999, we adopted two approaches. Firstly, we aimed to identify parameters associated with the appearance of lung tumors by univariate and multivariate analyses, and secondly, we examined those parameters that changed over time. Synchronous lung tumors were excluded in the first approach since the presence of synchronous lung metastases itself is defined as M1 as an explanatory variable. The analyses underscored parameters such as rectal cancer and the presence of lymph node and distant organ metastases at CRC surgery as predictive factors for late lung metastases (Table IV) . The second approach elucidated a different set of parameters; the 2000-2009 cohort included older patients, smaller CRC tumors, more frequent location in the right-sided colon, and higher percentages of distant metastases and a positive family history of CRC compared to the 1990-1999 cohort (Table V) ; therefore, the presence of distant metastases was the only factor commonly indicated by these comparison analyses. The number of stage IV CRC patients was 1.6-fold higher in 2000-2009 than in 1990-1999 (Table V) . It is well accepted that hematogenous metastases from CRC generally occur first in the liver, due to venous drainage via the portal system, and then later appear systemically, including in the lung. Consistent with this hypothesis, our results indicated that extra-pulmonary [such as hepatic (representing 74% in our study)] metastases were a risk factor for sequential lung metastases.
Surgical removal was beneficial to patients with lung metastases in our series, as reported previously (10), although there was a selection bias in the indications for metastasectomy in this retrospective study. As shown in Fig. 1A , the overall survival of CRC patients following metachronous pulmonary metastasectomy was largely in concordance with the 5-year survival rate of 24-68% reported previously (10) (11) (12) . It is noteworthy that CRC patients with inoperable lung metastases exhibited markedly more favorable prognosis in the second decade compared to the first decade (Fig. 1B) . Few studies have exclusively investigated the trend in the prognosis of unresect- (Table VI) . The majority of previous studies uniformly failed to define the size of the largest metastasis as a predictive factor for survival of CRC patients with pulmonary metastasectomy (11, 12, (14) (15) (16) (17) . Taken together, we envision that earlier detection of lung deposits as well as marked progress in multidisciplinary treatment, for example, effective chemotherapeutic regimens in combination with monoclonal antibodies (7), has resulted in prolonged survival in patients with unresectable lung metastases.
In conclusion, an increasing number of stage IV CRC patients underwent curative resection between 2000 and 2009 in our hospital, which resulted in a higher incidence of lung metastases detected in the follow-up period. Diagnostic and non-surgical therapeutic progress has been of particular benefit to CRC patients with inoperable lung metastases; therefore, it will be of greater importance to make accurate diagnosis of, and develop appropriate treatment strategies for, lung tumors observed in CRC cases. 
